Ozempic and Wegovi set off a domino effect as new products emerge across industries to capture new consumer habits – Novo Nordisk (NYSE:NVO), Eli Lilly and Company (NYSE:LLY)



20-year pro trader reveals “Moneyline”

Ditch the indicators and use the “Money Line”. A simple line that tells you when to buy or sell without the guesswork. It's the line on a chart that helped Nic Chahine win 83% of his options purchases. This is how he does it.


The rise of weight loss drugs Wegs and Munjaro by Novo Nordisk (NYSE:NVO) is a leader in new product development across a variety of segments.

what happenedCNBC reported Friday that companies ranging from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on changing consumer habits.

DSM Firmenich We are researching nutritional supplements that can complement the effects of these weight loss drugs. CEO Dimitri de Vries He told CNBC the move was a natural progression for the industry.

“Once they've committed to losing weight and are successful, they then move onto the health, nutrition and lifestyle counters because they basically want to maintain where they are now, and that's where we come in,” De Vries said.

Swiss food giant Nestle The company has launched a new frozen food range aimed at users of GLP-1 medications. Mark Schneider He stressed that while weight loss drugs change consumer behavior, nutritional needs do not change.

Danone CEO Antoine de Saint-Afrique The company also sees GLP-1 drugs as complementary to its nutritional products, potentially increasing demand for them.

Analysts remain cautious about the long-term impact of these drugs, with Barclays analysts suggesting that while GLP-1 drugs could potentially serve as a replacement for certain foods, they could also increase demand for healthier options.

Pharmaceutical packaging companies and airlines may also benefit from the growing market for weight loss drugs, but the full impact on various industries remains to be seen.

Also see: Ross Gerber warns 'Roaring Kitty' about short GameStop position, has many enemies: 'He

Why is this important: The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a huge increase from a previous forecast of $100 billion. This surge will be driven by Novo Nordisk and Eli Lilly.

But the surge also means there are counterfeit products on the market. Novo Nordisk recently filed a lawsuit against 21 U.S. medical spas, wellness clinics, and pharmacies for selling products that claim to contain semaglutide, the main ingredient in the popular weight-loss drug Wegobee. This brings the total number of lawsuits to 21 since June, and five companies have already been banned from selling the products in question.

Novo Nordisk also faces major challenges in China, where local pharmaceutical companies are developing generic versions of its flagship diabetes and obesity drugs. The patents for the active ingredients in those drugs are due to expire in China in 2026. An adverse court ruling could lead to the drugs' patent protection expiring early in China, making China the first major market to strip Novo Nordisk of its patent protection.

Read next: Rapper 50 Cent accepted Bitcoin as payment for his album 'Animal Ambition' 10 years ago: Here's how much he made from the cryptocurrency and how much it's worth today

Image courtesy of Shutterstock

This story was produced by Benzinga Neuro. Pooja Rajkumari


20-year pro trader reveals “Moneyline”

Ditch the indicators and use the “Money Line”. A simple line that tells you when to buy or sell without any guesswork. This is the line on a chart that helped Nic Chahine win 83% of his options purchases. This is how he does it.


Enter to win $500 in stock or cryptocurrency

Enter your email address to get Benzinga's Ultimate Morning Update, a free $30 Gift Card, and more.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *